Skye Bioscience, Inc. - 10-Q Filing
Skye Bioscience filed its quarterly report for the period ended March 31, 2026. The filing includes unaudited financial statements showing cash balances of $45 million as of March 31, 2026, and outlines plans to fund operations through existing resources for at least 12 months.
Tickers: $SKYE